Zymeworks Inc (ZYME)

$28.56 +0.46 (1.64%)
Market Cap 2.07B
Revenue (ttm) 105.97M
Net Income (ttm) -81.13M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 28.40
Profit Margin -76.56%
Debt to Equity Ratio 0.00
Volume 949,895
Avg Vol 651,820
Day's Range N/A - N/A
Shares Out 73.75M
Stochastic %K 70%
Beta 1.20
Analysts Strong Sell
Price Target $40.08

Company Profile

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-sp...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 274 8744
Address:
108 Patriot Drive, Suite A, Middletown, United States
maplelakeduckslayer
maplelakeduckslayer Apr. 27 at 2:07 PM
$ZYME FDA accepted Jazzs application for zani in gea, pdufa date August 25
0 · Reply
NyseDayTrader
NyseDayTrader Apr. 27 at 1:49 PM
$ZYME
0 · Reply
mostbullish
mostbullish Apr. 25 at 8:47 PM
$ZYME ZW191 AACR update: The breakout 📈speaks for itself. Float is verysmall on this one. ZW191 AACR update: • 61% cORR in platinum-resistant ovarian cancer (6.4–9.6 mg/kg) • Early Elahere ~30% ORR pooled / 47% selected subgroup → ZW191 showing stronger early efficacy signal • 100% disease control in optimized ovarian/endometrial cohorts • 1.4 month time to response = fast activity • 6.4 mg/kg emerging as likely sweet spot • Ongoing optimization trial now key catalyst: goal is preserve efficacy while lowering AEs • If durability holds + safety improves, ZW191 could become a serious next-gen FRα challenger I’m a bagholder and wont be selling :-) $ZYME #biotech #oncology
1 · Reply
NoBSPls
NoBSPls Apr. 24 at 10:25 PM
$ZYME What is the next catalyst for this one. I have a small position but it is hard to find any news
1 · Reply
BuyingSheep
BuyingSheep Apr. 24 at 8:47 AM
$ZYME Wow, despite all the posters of pre-clinical data, this turd is hardly moving sideways. 🤡 Very god sign for a dump coming very soon.... 📉
3 · Reply
BoilerTruth
BoilerTruth Apr. 22 at 8:05 PM
$ZYME when stocks are well behaved. Nice close 💪
0 · Reply
JesseJames87
JesseJames87 Apr. 22 at 1:58 PM
$ZYME 52 week high!
1 · Reply
buzzkiller
buzzkiller Apr. 22 at 1:09 PM
$ZYME
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Apr. 21 at 11:07 PM
$ZYME really solid data. 61% Corr is nice. Zani was 69% for he's and look where that got them
3 · Reply
NyseDayTrader
NyseDayTrader Apr. 21 at 8:12 PM
$ZYME 💪 Like bull!
0 · Reply
Latest News on ZYME
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Apr 21, 2026, 5:30 PM EDT - 5 days ago

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Apr 21, 2026, 9:30 AM EDT - 6 days ago

Zymeworks Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Apr 17, 2026, 3:00 PM EDT - 10 days ago

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Apr 16, 2026, 6:00 AM EDT - 11 days ago

Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026

Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 10:15 AM EDT - 12 days ago

Zymeworks Transcript: 25th Annual Needham Virtual Healthcare Conference

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Apr 9, 2026, 6:00 AM EDT - 18 days ago

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Apr 1, 2026, 6:00 AM EDT - 26 days ago

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Mar 30, 2026, 6:00 AM EDT - 4 weeks ago

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Zymeworks Announces Participation in Upcoming Investor Conferences

Mar 24, 2026, 6:00 AM EDT - 4 weeks ago

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Mar 18, 2026, 7:46 AM EDT - 5 weeks ago

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Mar 17, 2026, 5:02 PM EDT - 5 weeks ago

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Zymeworks Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 10:10 AM EDT - 6 weeks ago

Zymeworks Transcript: The Citizens Life Sciences Conference 2026

Zymeworks Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 3:00 PM EDT - 7 weeks ago

Zymeworks Transcript: Leerink Global Healthcare Conference 2026

Zymeworks Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 2:30 PM EST - 2 months ago

Zymeworks Transcript: TD Cowen 46th Annual Health Care Conference

Zymeworks Earnings Call Transcript: Q4 2025

Mar 2, 2026, 8:30 AM EST - 2 months ago

Zymeworks Earnings Call Transcript: Q4 2025

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Mar 2, 2026, 6:01 AM EST - 2 months ago

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 6:00 AM EST - 2 months ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Feb 12, 2026, 6:00 AM EST - 2 months ago

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Zymeworks Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:00 PM EST - 3 months ago

Zymeworks Transcript: 44th Annual J.P. Morgan Healthcare Conference

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Jan 12, 2026, 6:00 AM EST - 3 months ago

Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Jan 11, 2026, 6:00 PM EST - 3 months ago

Zymeworks Outlines Strategic Priorities and Outlook for 2026

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Jan 6, 2026, 1:34 PM EST - 3 months ago

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

Zymeworks Announces Participation in Upcoming Conferences

Dec 2, 2025, 4:05 PM EST - 5 months ago

Zymeworks Announces Participation in Upcoming Conferences

Zymeworks Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:00 AM EST - 5 months ago

Zymeworks Transcript: Evercore ISI 8th Annual HealthCONx Conference

Zymeworks Transcript: Investor Update

Nov 18, 2025, 8:30 AM EST - 5 months ago

Zymeworks Transcript: Investor Update

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Nov 18, 2025, 1:01 AM EST - 5 months ago

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Nov 18, 2025, 1:00 AM EST - 5 months ago

Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

Nov 17, 2025, 12:09 PM EST - 5 months ago

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

JAZZ

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

Nov 17, 2025, 8:10 AM EST - 5 months ago

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

JAZZ

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Nov 17, 2025, 6:00 AM EST - 5 months ago

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

Zymeworks Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:30 PM EST - 6 months ago

Zymeworks Earnings Call Transcript: Q3 2025

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 6 months ago

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Zymeworks Transcript: Study Result

Oct 23, 2025, 3:30 PM EDT - 6 months ago

Zymeworks Transcript: Study Result

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Oct 23, 2025, 12:30 PM EDT - 6 months ago

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Oct 16, 2025, 6:00 AM EDT - 6 months ago

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

Oct 13, 2025, 4:00 PM EDT - 7 months ago

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Oct 9, 2025, 8:30 AM EDT - 7 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

INM

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Oct 9, 2025, 6:00 AM EDT - 7 months ago

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

Zymeworks Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 4:30 PM EDT - 8 months ago

Zymeworks Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Sep 2, 2025, 12:30 PM EDT - 8 months ago

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit

Zymeworks halts development of cancer drug after trial setback

Sep 2, 2025, 6:18 AM EDT - 8 months ago

Zymeworks halts development of cancer drug after trial setback

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Sep 2, 2025, 6:00 AM EDT - 8 months ago

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Aug 11, 2025, 6:00 AM EDT - 9 months ago

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

Zymeworks Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Zymeworks Earnings Call Transcript: Q2 2025

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Jul 28, 2025, 6:00 AM EDT - 9 months ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Jul 17, 2025, 6:00 AM EDT - 10 months ago

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Zymeworks Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 2:00 PM EDT - 11 months ago

Zymeworks Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 30, 2025, 6:00 AM EDT - 11 months ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 22, 2025, 5:00 PM EDT - 1 year ago

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 19, 2025, 4:15 PM EDT - 1 year ago

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Zymeworks Earnings Call Transcript: Q1 2025

May 8, 2025, 4:30 PM EDT - 1 year ago

Zymeworks Earnings Call Transcript: Q1 2025

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 1 year ago

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Apr 25, 2025, 1:00 PM EDT - 1 year ago

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Apr 21, 2025, 6:00 AM EDT - 1 year ago

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Apr 17, 2025, 6:00 AM EDT - 1 year ago

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 1 year ago

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Mar 6, 2025, 1:18 PM EST - 1 year ago

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Zymeworks Earnings Call Transcript: Q4 2024

Mar 5, 2025, 4:30 PM EST - 1 year ago

Zymeworks Earnings Call Transcript: Q4 2024

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 4:05 PM EST - 1 year ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Feb 26, 2025, 6:00 AM EST - 1 year ago

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Zymeworks Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Feb 20, 2025, 2:00 PM EST - 1 year ago

Zymeworks Transcript: Citi's 2025 Virtual Oncology Leadership Summit

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Feb 18, 2025, 6:00 AM EST - 1 year ago

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Feb 13, 2025, 6:00 AM EST - 1 year ago

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Zymeworks Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 16, 2025, 11:15 AM EST - 1 year ago

Zymeworks Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Jan 8, 2025, 4:05 PM EST - 1 year ago

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Zymeworks Transcript: Status Update

Dec 12, 2024, 8:30 AM EST - 1 year ago

Zymeworks Transcript: Status Update

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Nov 21, 2024, 6:00 AM EST - 1 year ago

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Nov 5, 2024, 6:00 AM EST - 1 year ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Zymeworks Earnings Call Transcript: Q3 2024

Oct 31, 2024, 4:30 PM EDT - 1 year ago

Zymeworks Earnings Call Transcript: Q3 2024

Zymeworks Earnings Call Transcript: Q2 2024

Aug 1, 2024, 4:30 PM EDT - 1 year ago

Zymeworks Earnings Call Transcript: Q2 2024

Zymeworks Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 12, 2024, 2:00 PM EDT - 2 years ago

Zymeworks Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Zymeworks Transcript: Jefferies Global Healthcare Conference

Jun 5, 2024, 10:30 AM EDT - 2 years ago

Zymeworks Transcript: Jefferies Global Healthcare Conference

Zymeworks Earnings Call Transcript: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Zymeworks Earnings Call Transcript: Q1 2024

Zymeworks Transcript: Bloom Burton & Co. Healthcare Investor Conference

Apr 16, 2024, 2:00 PM EDT - 2 years ago

Zymeworks Transcript: Bloom Burton & Co. Healthcare Investor Conference

Zymeworks Transcript: Stifel Virtual Targeted Oncology Days Conference

Apr 16, 2024, 12:30 PM EDT - 2 years ago

Zymeworks Transcript: Stifel Virtual Targeted Oncology Days Conference

Zymeworks Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 11, 2024, 11:45 AM EDT - 2 years ago

Zymeworks Transcript: 23rd Annual Needham Virtual Healthcare Conference

Zymeworks Earnings Call Transcript: Q4 2023

Mar 6, 2024, 4:30 PM EST - 2 years ago

Zymeworks Earnings Call Transcript: Q4 2023

Zymeworks Transcript: TD Cowen 44th Annual Health Care Conference 2024

Mar 6, 2024, 11:10 AM EST - 2 years ago

Zymeworks Transcript: TD Cowen 44th Annual Health Care Conference 2024

Zymeworks Transcript: Citi 2024 Virtual Oncology Leadership Summit

Feb 22, 2024, 11:00 AM EST - 2 years ago

Zymeworks Transcript: Citi 2024 Virtual Oncology Leadership Summit

Zymeworks Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 13, 2024, 9:20 AM EST - 2 years ago

Zymeworks Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference

Zymeworks Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 8, 2024, 2:30 PM EST - 2 years ago

Zymeworks Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Zymeworks Transcript: The J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 11, 2024, 11:15 AM EST - 2 years ago

Zymeworks Transcript: The J.P. Morgan 42nd Annual Healthcare Conference 2024

Zymeworks Transcript: 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 2:10 PM EST - 2 years ago

Zymeworks Transcript: 6th Annual Evercore ISI HealthCONx Conference

Zymeworks Transcript: Jefferies London Healthcare Conference 2023

Nov 14, 2023, 6:30 AM EST - 2 years ago

Zymeworks Transcript: Jefferies London Healthcare Conference 2023

Zymeworks Earnings Call Transcript: Q3 2023

Nov 7, 2023, 4:30 PM EST - 2 years ago

Zymeworks Earnings Call Transcript: Q3 2023

Zymeworks Transcript: Morgan Stanley 21st Annual Global Healthcare Conference

Sep 12, 2023, 7:30 AM EDT - 2 years ago

Zymeworks Transcript: Morgan Stanley 21st Annual Global Healthcare Conference

Zymeworks Transcript: Citi 18th Annual BioPharma Conference

Sep 6, 2023, 10:30 AM EDT - 2 years ago

Zymeworks Transcript: Citi 18th Annual BioPharma Conference

Zymeworks Earnings Call Transcript: Q2 2023

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Zymeworks Earnings Call Transcript: Q2 2023

Zymeworks Transcript: Bank of America Securities 2023 Healthcare Conference

May 11, 2023, 11:55 AM EDT - 3 years ago

Zymeworks Transcript: Bank of America Securities 2023 Healthcare Conference

Zymeworks Earnings Call Transcript: Q1 2023

May 8, 2023, 4:30 PM EDT - 3 years ago

Zymeworks Earnings Call Transcript: Q1 2023

Zymeworks Earnings Call Transcript: Q4 2022

Mar 7, 2023, 4:30 PM EST - 3 years ago

Zymeworks Earnings Call Transcript: Q4 2022

Zymeworks Transcript: JPMorgan Healthcare Conference

Jan 12, 2023, 1:30 PM EST - 3 years ago

Zymeworks Transcript: JPMorgan Healthcare Conference

Zymeworks Transcript: Study Result

Dec 19, 2022, 10:00 AM EST - 3 years ago

Zymeworks Transcript: Study Result

Zymeworks Earnings Call Transcript: Q3 2022

Nov 8, 2022, 4:30 PM EST - 3 years ago

Zymeworks Earnings Call Transcript: Q3 2022

Zymeworks Transcript: R&D Day 2022

Oct 20, 2022, 8:00 AM EDT - 3 years ago

Zymeworks Transcript: R&D Day 2022

Zymeworks Transcript: Investor Update

Oct 19, 2022, 7:00 AM EDT - 3 years ago

Zymeworks Transcript: Investor Update

Zymeworks Transcript: Study Result

Sep 12, 2022, 4:30 PM EDT - 3 years ago

Zymeworks Transcript: Study Result

Zymeworks Earnings Call Transcript: Q2 2022

Aug 3, 2022, 10:43 PM EDT - 4 years ago

Zymeworks Earnings Call Transcript: Q2 2022

Zymeworks Transcript: Status Update

Jul 15, 2022, 9:00 AM EDT - 4 years ago

Zymeworks Transcript: Status Update

Zymeworks Transcript: Status Update

Jun 6, 2022, 4:30 PM EDT - 4 years ago

Zymeworks Transcript: Status Update

Zymeworks Earnings Call Transcript: Q1 2022

May 4, 2022, 5:52 AM EDT - 4 years ago

Zymeworks Earnings Call Transcript: Q1 2022

Zymeworks Earnings Call Transcript: Q4 2021

Feb 24, 2022, 9:12 AM EST - 4 years ago

Zymeworks Earnings Call Transcript: Q4 2021

Zymeworks Transcript: Study Update

Nov 9, 2021, 4:15 PM EST - 4 years ago

Zymeworks Transcript: Study Update

Zymeworks Transcript: Status Update

Sep 16, 2021, 7:30 AM EDT - 5 years ago

Zymeworks Transcript: Status Update

maplelakeduckslayer
maplelakeduckslayer Apr. 27 at 2:07 PM
$ZYME FDA accepted Jazzs application for zani in gea, pdufa date August 25
0 · Reply
NyseDayTrader
NyseDayTrader Apr. 27 at 1:49 PM
$ZYME
0 · Reply
mostbullish
mostbullish Apr. 25 at 8:47 PM
$ZYME ZW191 AACR update: The breakout 📈speaks for itself. Float is verysmall on this one. ZW191 AACR update: • 61% cORR in platinum-resistant ovarian cancer (6.4–9.6 mg/kg) • Early Elahere ~30% ORR pooled / 47% selected subgroup → ZW191 showing stronger early efficacy signal • 100% disease control in optimized ovarian/endometrial cohorts • 1.4 month time to response = fast activity • 6.4 mg/kg emerging as likely sweet spot • Ongoing optimization trial now key catalyst: goal is preserve efficacy while lowering AEs • If durability holds + safety improves, ZW191 could become a serious next-gen FRα challenger I’m a bagholder and wont be selling :-) $ZYME #biotech #oncology
1 · Reply
NoBSPls
NoBSPls Apr. 24 at 10:25 PM
$ZYME What is the next catalyst for this one. I have a small position but it is hard to find any news
1 · Reply
BuyingSheep
BuyingSheep Apr. 24 at 8:47 AM
$ZYME Wow, despite all the posters of pre-clinical data, this turd is hardly moving sideways. 🤡 Very god sign for a dump coming very soon.... 📉
3 · Reply
BoilerTruth
BoilerTruth Apr. 22 at 8:05 PM
$ZYME when stocks are well behaved. Nice close 💪
0 · Reply
JesseJames87
JesseJames87 Apr. 22 at 1:58 PM
$ZYME 52 week high!
1 · Reply
buzzkiller
buzzkiller Apr. 22 at 1:09 PM
$ZYME
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Apr. 21 at 11:07 PM
$ZYME really solid data. 61% Corr is nice. Zani was 69% for he's and look where that got them
3 · Reply
NyseDayTrader
NyseDayTrader Apr. 21 at 8:12 PM
$ZYME 💪 Like bull!
0 · Reply
BioRich
BioRich Apr. 21 at 3:47 AM
$ZYME $KYTX and $CADL lead next potential M&A targets after Kelonia deal with $LLY today. Who's next?
1 · Reply
outlawinvestor1
outlawinvestor1 Apr. 20 at 7:08 PM
$ZYME https://x.com/raffcolo/status/2046263881337798684?s=20
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Apr. 19 at 12:26 AM
$ZYME
1 · Reply
howardlindzon
howardlindzon Apr. 15 at 11:24 PM
$ZYME been a beuaty ...(no position)
0 · Reply
RonIsWrong
RonIsWrong Apr. 15 at 9:55 PM
$ZYME 👀 perceptive added 712,729 shares
1 · Reply
NyseDayTrader
NyseDayTrader Apr. 15 at 8:36 PM
$ZYME OK, OK. Slow and steady wins the race.
0 · Reply
BoilerTruth
BoilerTruth Apr. 14 at 2:00 PM
$ZYME
2 · Reply
maplelakeduckslayer
maplelakeduckslayer Apr. 14 at 1:16 AM
$ZYME @BuyingSheep about to get ass blasted next week with multiple data readouts This guy honestly has to be part of the butt hurt All Blue Falcons pissed zyme didn't sell out to them for $10 a share. Main guy is based in Canada
1 · Reply
BuyingSheep
BuyingSheep Apr. 13 at 4:56 PM
$ZYME https://www.marketbeat.com/instant-alerts/filing-jpmorgan-chase-co-cuts-stock-position-in-zymeworks-inc-zyme-2026-04-13/
1 · Reply
BuyingSheep
BuyingSheep Apr. 13 at 11:11 AM
$ZYME https://finance.yahoo.com/sectors/healthcare/articles/zymeworks-announces-additional-leadership-appointments-100000397.html Wow, these leadership appointments are making a hell of sense now…. send it. 📉📉📉
1 · Reply
maplelakeduckslayer
maplelakeduckslayer Apr. 11 at 2:11 PM
$ZYME ⬇️
1 · Reply
BuyingSheep
BuyingSheep Apr. 10 at 6:01 PM
$ZYME what a huge dump out of this $27 supply zone. Be prepared for more.
1 · Reply